Skip to main content

Table 2 Demographics, clinical characteristics and outcome (week 24) of the study populations

From: Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)

Parameter

Sub-parameter

Immediate treatment

Deferred treatment

p-value (if applicable)

Eventa (frequency row %)

No event

22 (70.97)

21 (70.00)

0.934 (computed by Chi-square)

Event

9 (29.03)

9 (30.00)

Hospitalization (days)

Mean (absolute)

33.2 ± 19.1

34.57 ± 23.6

0.6125 (computed by t-test)

Range (absolute)

141

205

Incidence of IRIS (%)

Yes

11 (35.48)

10 (33.33)

0.8597 (computed by Chi-square)

No

20 (64.52)

20 (66.67)

Virological outcome week 24 (more than 400 or 50 copies/mL)

Number of patients with HIV RNA > 50 cop/mL

12

12

0.6740 (computed by Chi-square)

With HIV RNA > 400 cop/mL

1

1

1.0 (computed by Fisher’s Exact test)

Immunological outcome (week 24): CD4 cells

Absolute mean

126 (± 42.1)

137 (± 44.0)

0.6421 (computed by t-test)

Delta mean

99

95

Quality of life

SF 36 body score (sum of scores)

5706

5772

0.7978

SF 36 psychological score (sum of scores)

5622

5106

0.7978 (each computed by Wilcoxon test)

AE-severity by treatment (%)

Grade 1 event

61 (22.26)

73 (26.64)

0.4682 (computed by Fisher’s Exact test)

Grade 2 event

53 (19.34)

55 (20.07)

Grade 3 event

6 (2.19)

11 (4.01)

Grade 4 event

3 (1.09)

6 (2.19)

Unknown severity

1 (0.38)

5 (1.82)

Total

124 (45.26)

150 (54.74)

 

PCP

 

4 events

6 events

0.6372 (number of events between TE/PCP; computed by Chi-square)

TE

 

5 events

3 events

  1. Italicized values are standard-deviations of the mean-values
  2. aDefinition of event: death, all new or relapsing OI, other grade 4 (G4) clinical endpoint within 24 weeks (see “Methods” section)